small molecule

TYBOST

COBICISTAT

Loss of exclusivityApril 2033latest FDA-listed patent expiry

CompanyGilead Sciences →See this company's full patent-cliff portfolio

Drug detail

Brand name	TYBOST
Active ingredient	COBICISTAT
Strength	150MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	September 2014
Marketing status	DISCN

Listed patents

Patent	Expires	Type
10039718*PED	April 2033	—
10039718	October 2032	product
8148374*PED	March 2030	—
8148374	September 2029	substance, product

Regulatory exclusivity

Code	Expires
ODE-260	August 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Gilead Sciences